NOVATO, Calif., July 14 /CNW/ -- Raptor Pharmaceuticals Corp. (OTC
Bulletin Board: RPTP), today announced the appointments of Richard L.
Franklin, M.D., Ph.D. to the Company's board of directors and Stephen C.
Blacklow, M.D., Ph.D. to its scientific advisory board.
(Photo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )
Christopher M. Starr, Ph.D., co-founder and CEO of Raptor Pharmaceuticals
Corp., stated, "I would like to welcome Drs. Franklin and Blacklow as valuable
additions to our board of directors and scientific advisory board,
respectively. Dr. Franklin's background is a unique combination of
considerable knowledge in areas of biomedical science, particularly in
neurology and cancer, as well as years of experience in corporate leadership
and finance. We expect to leverage his scientific and investment banking
expertise to help guide Raptor's clinical development programs and our
corporate strategy towards maximizing stockholder value while addressing
critically compelling and unmet medical needs.
"Dr. Blacklow is an internationally recognized scientist," continued
Starr. "He has made scientific breakthroughs working with the
receptor-associated protein, also known as RAP which is the backbone of
Raptor's drug discovery and preclinical efforts. He is expected to provide
valuable insight regarding our early-stage programs and adds further expertise
to Raptor's already established and distinguished scientific team."
Dr. Franklin has 25 years of experience in the biomedical industry. He is
currently Chairman of Synthemed, Inc., a publicly traded medical device
company; and DMS Data Systems, an Internet-based information services company.
He is also Executive Chairman of Tarix, a subsidiary of medical products
company, Phairson, Ltd, where he sits on the board of directors. During his
career, Dr. Franklin has founded a healthcare consulting firm, Richard
Franklin & Associates, and led the Healthcare Corporate Finance Team at Tucker
Anthony, an investment bank. He received a bachelor's degree from Harvard
University, an M.A. in mathematics from the University of Washington, a Ph.D.
in mathematics from Brandeis University, and an M.D. from Boston University
School of Medicine.
Dr. Franklin stated, "As a member of Raptor's board of directors, I look
forward to counseling the Company on maximizing the pipeline's potential and
delivering value to stockholders. Raptor's scientific expertise and drug
discovery capabilities, coupled with a focus on mid-stage clinical studies
evaluating novel formulations of existing drugs, strikes the right balance.
The drug development risks inherent in preclinical programs are nicely offset
by the recently acquired clinical programs focused on reformulating currently
approved therapies with known safety profiles and repurposing approved
therapies for new indications."
Dr. Blacklow contributes scientific exerptise from academia to Raptor's
scientific advisory board. He is an Associate Professor of Pathology and a
Director of the M.D. Ph.D. program, basic sciences track, at Harvard Medical
School. He also directs a research laboratory at the Brigham and Women's
Hospital, a teaching affiliate of Harvard Medical School. Recently, Dr.
Blacklow's team determined the structure of the RAP d3 protein complexed with
receptor. Over the last ten years, Dr. Blacklow's research team has achieved
international recognition for mechanistic and structural studies of
low-density lipoprotein or LDL receptor proteins, and for work on the
structure and function of human Notch proteins. Dr. Blacklow received his M.D.
and Ph.D. in bioorganic chemistry from Harvard University in 1991.
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage
biopharmaceutical company leveraging novel drug-targeting platforms and
enhanced drug formulations to improve treatment outcomes among patients with
liver disorders, infectious diseases, cancer, and various orphan indications.
The Company's clinical division advances internally developed and in-licensed
clinical-stage product candidates towards marketing approval and
commercialization and is currently running clinical trials in patients with
aldehyde dehydrogenase ("ALDH2") deficiency and nephropathic cystinosis.
Raptor's preclinical division bioengineers novel drug candidates and
drug-targeting platforms derived from the human receptor-associated protein
("RAP") and related proteins to target cancer, neurodegenerative disorders and
For additional information, please visit www.raptorpharma.com.
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. These statements
relate to future events or our future results of operation or future financial
performance, including, but not limited to the following statements: Dr.
Franklin's ability to increase stockholder value; Dr. Blacklow's ability to
add value to our preclinical programs; and the Company's ability to develop,
obtain regulatory approval and commercialize its clinical and preclinical
product candidate programs. These statements are only predictions and involve
known and unknown risks, uncertainties and other factors, which may cause our
actual results to be materially different from these forward-looking
statements. Factors which may significantly change or prevent our forward
looking statements from fruition include that we may be unsuccessful in
developing any products or acquiring products; that our technology may not be
validated as we progress further and our methods may not be accepted by the
scientific community; that we are unable to retain or attract key employees
whose knowledge is essential to the development of our products; that
unforeseen scientific difficulties develop with our process; that our patents
are not sufficient to protect essential aspects of our technology; that
competitors may invent better technology; that our products may not work as
well as hoped or worse, that our products may harm recipients; and that we may
not be able to raise sufficient funds for development or working capital when
we require it. As well, our products may never develop into useful products
and even if they do, they may not be approved for sale to the public. We
caution readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they were made. Certain of these
risks, uncertainties, and other factors are described in greater detail in our
filings from time to time with the Securities and Exchange Commission (the
"SEC"), which we strongly urge you to read and consider, including our
Registration Statement on Form SB-2, as amended, that was declared effective
on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on
November 14, 2007; and our Form 10-QSB filed with the SEC on July 9, 2008, all
of which are available free of charge on the SEC's web site at
http://www.sec.gov. Subsequent written and oral forward-looking statements
attributable to us or to persons acting on our behalf are expressly qualified
in their entirety by the cautionary statements set forth in our reports filed
with the SEC. We expressly disclaim any intent or obligation to update any
For more information, please contact:
The Ruth Group
Sara Ephraim (investors) Janine McCargo (media)
(646) 536-7002 (646) 536-7033
For further information:
For further information: Investors, Sara Ephraim, +1-646-536-7002,
email@example.com, Media, Janine McCargo, +1-646-536-7033,
firstname.lastname@example.org, both of The Ruth Group for Raptor Pharmaceuticals
Corp. Web Site: http://www.raptorpharma.com